Detection Rates of Suspected Lesions and Equivocal Lesions and Testing of Equality for Detection of Suspected Lesions Between 18F-DCFPyL and 18F-PSMA-1007 According to Primary Staging, Biochemical Recurrence, and Follow-up of Systemic Therapies
| Primary staging (n = 69) | BCR (n = 21) | Follow-up (n = 30) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 18F-DCFPyL | 18F-PSMA-1007 | P | 18F-DCFPyL | 18F-PSMA-1007 | P | 18F-DCFPyL | 18F-PSMA-1007 | P | ||||||||
| Reader | Site | SM | Eq. | SM | Eq. | SM | Eq. | SM | Eq. | SM | Eq. | SM | Eq. | |||
| 1 | Prostate | 66 (96) | 2 (3) | 67 (97) | 2 (3) | 0.669 | 6 (29) | 0 (0) | 13 (62) | 3 (14) | 0.007* | 14 (47) | 2 (7) | 9 (30) | 2 (7) | 0.186 |
| Lymph nodes | 24 (35) | 1 (1) | 27 (39) | 4 (6) | 0.393 | 11 (52) | 1 (5) | 9 (43) | 1 (5) | 0.532 | 17 (57) | 0 (0) | 20 (67) | 0 (0) | 0.430 | |
| Whole skeleton | 17 (25) | 1 (1) | 20 (29) | 11 (16) | 0.065 | 2 (10) | 1 (5) | 6 (29) | 5 (24) | 0.013* | 20 (67) | 1 (3) | 24 (80) | 1 (3) | 0.234 | |
| 2 | Prostate | 67 (97) | 2 (3) | 68 (99) | 1 (1) | 0.572 | 6 (29) | 1 (5) | 13 (62) | 0 (0) | 0.029* | 13 (43) | 2 (7) | 21 (70) | 0 (0) | 0.059 |
| Lymph nodes | 25 (36) | 4 (6) | 28 (41) | 4 (6) | 0.595 | 11 (52) | 0 (0) | 7 (33) | 1 (5) | 0.285 | 19 (63) | 0 (0) | 22 (73) | 1 (3) | 0.356 | |
| Whole skeleton | 15 (22) | 2 (3) | 15 (22) | 27 (39) | 0.001* | 3 (14) | 2 (10) | 7 (33) | 9 (43) | 0.003* | 18 (60) | 1 (3) | 22 (73) | 4 (13) | 0.154 |
↵* Statistically significant (P < 0.05; Mann–Whitney U test).
BCR = biochemical recurrence; SM = suspected malignant; Eq. = equivocal.
Data are number followed by percentage in parentheses. Suspected malignant PSMA is RADS 4 and 5; equivocal PSMA is RADS 3a, 3b, 3c, and 3d.